Objective: To investigate the predictive value of serum C3 and C4 complement component levels in relation to pregnancy outcome in patients with antiphospholipid syndrome (APS). Materials and methods: A prospective study of 47 pregnancies associated with APS was performed. Pregnancy outcome was analyzed in terms of: fetal loss, preterm delivery ( 34 gestational weeks), fetal intrauterine growth restriction (IUGR), birth weight <2500 g and preeclampsia.
Introduction
Emerging evidence shows that not only thrombotic phenomena but also inflammatory events should be recognized as pathogenetic factors for pregnancy failure in antiphospholipid syndrome (APS). In particular, several reports suggest that the complement pathway may mediate fetal damage in APS. 1, 2 In our preliminary study, low levels of serum complement components were recognized as a negative prognostic factor for pregnancy outcome in APS patients. 3 In the present report, serum C3 and C4 complement component levels were prospectively investigated and related to pregnancy outcome in a larger population of patients with APS, in order to assess their role as a prognostic factor for pregnancy outcome.
Materials and methods
Forty-seven pregnancies associated with primary APS (PAPS) or secondary APS (sAPS), according to the revised classification criteria, 4 were prospectively followed in our tertiary referral centre from 2005 to 2009. Exclusion criterion was the presence of active Systemic Lupus Erythematosus (SLE) in the last six months before pregnancy. All patients were treated with a conventional protocol treatment including low-dose aspirin (LDA) and low molecular weight heparin (LMWH). 5 and/or C4 <10 mg/dl, positivity for anti-dsDNA and triple positivity for antiphospholipid antibodies (aPL) were related to pregnancy outcome. The following indicators of pregnancy outcome were considered for the analysis: fetal loss, preterm delivery 34 gestational weeks, fetal intrauterine growth restriction (IUGR), birth weight <2500 g, preeclampsia.
Week at delivery, neonatal birth weight and neonatal birth weight percentile were also investigated. Normally distributed continuous variables were compared using a two-sample Student t test, nominal variables were compared using a Chi square test. Variables significantly associated with the outcomes in the univariate analysis were convened into a logistic regression model including clinical and obstetric history features, infectious agents screening results 6 and uterine arteries Doppler velocimetry findings. 7
Results
Pregnancies were associated with PAPS in 63.8% of cases (n ¼ 30) and with sAPS in 36.2% of cases (n ¼ 17). As regard to aPL laboratory results, lupus anticoagulant resulted positive in 74% of cases, IgG and/or IgM anticardiolipin antibodies in 74% of cases and IgG and/or IgM anti-b2glicoprotein I antibodies in 39% of cases. Triple aPL positivity was found in 36% of pregnancies. Positivity for anti-dsDNA was detected in six pregnancies (12.7%) including five with sAPS and one with PAPS. Hypocomplementemia was diagnosed in 16 cases (34.0%), including seven with sAPS and nine with PAPS. Low C3 alone was found in 11 pregnancies (69%), low C4 alone in three pregnancies (19%) and both low C3 and C4 in two pregnancies (12%). No increase of lupus activity during pregnancy was noticed: all women with SLE maintained inactive or mildly active lupus during pregnancy (SLEDAI score 5). Four of 47 pregnancies ended in fetal loss (8.5%). Forty-three pregnancies ended in live births with a preterm delivery rate of 53.4%. Univariate analysis showed that fetal loss was statistically significantly associated with anti-dsDNA positivity (p ¼ 0.007) and with hypocomplementemia (p ¼ 0.019). Preterm delivery 34 gestational weeks and birth weight <2500 g were statistically significantly associated with hypocomplementemia (p ¼ 0.0002 and p < 0.0001, respectively). However, neither IUGR nor preeclampsia showed an association with hypocomplementemia, triple aPL positivity and anti-ds-DNA positivity. A lower neonatal birth weight, a lower neonatal birth weight percentile and an earlier week at delivery were found in pregnancies complicated by hypocomplementemia (p < 0.0001, p ¼ 0.0003, p < 0.0001 respectively) and triple aPL positivity (p ¼ 0.008, p ¼ 0.014, p ¼ 0.03 respectively). To highlight the role of complement activation in aPL related adverse pregnancy outcome, the population was divided into pregnancies associated with PAPS and sAPS (Table 1) . Also in the PAPS pregnancies group a poor pregnancy outcome was statistically significantly associated with hypocomplementemia. Multivariate analysis confirmed that hypocomplementemia was an independent predictor of lower neonatal birth weight (p ¼ 0.0001, ß ¼ À826.8 g) and lower week at delivery (p ¼ 0.002, ß ¼ À2.7 weeks).
Discussion
Uncontrolled complement activation has increasingly been recognized to play a critical role in the pathogenesis of aPL-induced placental damage. However, the association between complement activation and pregnancy outcome has been poorly studied. In this report, according to our previous observations, 3 low circulating levels of complement components were found to be associated with a poor pregnancy outcome, in terms of gestational week at delivery, neonatal birth weight, neonatal birth weight percentile, fetal loss, preterm delivery and birth weight < 2500 g.
In pregnancies with SLE the clinical utility of measuring complement and anti-dsDNA to predict pregnancy outcome is recently demonstrated; 8 in APS pregnancies our results suggest that hypocomplementemia could be considered a novel prognostic factor of poor pregnancy outcome, in addition to well-known risk factors, such as triple aPL positivity, 9 hypertension at conception and presence of abnormal uterine arteries Doppler findings. 10, 11 Moreover for the first time, these results revealed that hypocomplementemia could be a remarkable predictor of pregnancy outcome also in PAPS. Low levels of circulating complement components could be used to identify APS pregnancies at higher risk of obstetric complications; on the other hand, finding a normal complementemia could be an useful tool for reassuring counseling, also at the beginning of pregnancy. However, the small number of pregnancies and the absence of controls in the present study make necessary a larger prospective study to better define the exact role of measuring complement in the obstetric management of APS.
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